Campath-1H in renal transplantation: The University of Wisconsin experience.

Published

Journal Article

BACKGROUND: Immune cell depletion is known to prevent renal allograft rejection and injury. We evaluated the humanized monoclonal antibody Campath-1H (alemtuzumab; ILEX Oncology, San Antonio, Texas) in renal transplant recipients for its safety and efficacy in preventing rejection when used in combination with a calcineurin inhibitor, mycophenolate mofetil, and low-dose steroid therapy. METHODS: One hundred twenty-six consecutive renal allograft recipients received 2 doses of Campath-1H antibody on days 0 and 1. Outcomes were compared to patients who received an anti-CD25 antibody (n=799), Thymoglobulin (n=160), or other antibody treatment (n=156) in combination with a calcineurin inhibitor, mycophenolate mofetil, and higher dose steroids. RESULTS: The Campath-1H group overall experienced less rejection than the other 3 groups (P=.037). Patients with delayed graft function experienced less rejection with Campath-1H than control groups (P=.0096) and improved graft survival (P=.0119). There was no difference in infection or malignancies between the 4 groups. CONCLUSIONS: Campath-1H was well tolerated in renal transplant patients and led to significant reductions in incidence of rejection. Patients with delayed graft function experienced significantly improved graft survival.

Full Text

Duke Authors

Cited Authors

  • Knechtle, SJ; Fernandez, LA; Pirsch, JD; Becker, BN; Chin, LT; Becker, YT; Odorico, JS; D'alessandro, AM; Sollinger, HW

Published Date

  • October 2004

Published In

Volume / Issue

  • 136 / 4

Start / End Page

  • 754 - 760

PubMed ID

  • 15467659

Pubmed Central ID

  • 15467659

International Standard Serial Number (ISSN)

  • 0039-6060

Digital Object Identifier (DOI)

  • 10.1016/j.surg.2004.06.015

Language

  • eng

Conference Location

  • United States